Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-26T15:37:41.251Z Has data issue: false hasContentIssue false
  • English
  • Français

Child neurodevelopment following exposure to venlafaxine in utero, unexposed siblings as comparison groups: Preliminary results

Published online by Cambridge University Press:  16 April 2020

I. Nulman ,
D. Knittel-Keren ,
S. Valo ,
R. Sussman ,
M. Barrera  and
G. Koren
I. Nulman
Affiliation:
Motherisk Program, Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, ON, Canada
D. Knittel-Keren
Affiliation:
Motherisk Program, Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, ON, Canada
S. Valo
Affiliation:
Motherisk Program, Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, ON, Canada
R. Sussman
Affiliation:
Motherisk Program, Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, ON, Canada
M. Barrera
Affiliation:
Department of Psychology, Hospital for Sick Children, Toronto, ON, Canada
G. Koren
Affiliation:
Motherisk Program, Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, ON, Canada

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background/Aim

Venlafaxine (VLF) is an antidepressant drug often used by pregnant women. Its possible adverse effects on fetal CNS development have not been studied. The present study will fill the knowledge gap.

Aim:

To assess neurodevelopment of children exposed to VLF during gestation.

Methods:

Cohort study -controlled, matched, and blinded. Assessment of 5 groups of mother-child pairs: exposed to VLF (n=32) or other SRIs (n=29), healthy controls (n=42), and 2 groups of siblings (n=15). Siblings were unexposed relatives of children from the VLF or ‘other SRIs’ groups. Primary outcome: WPPSI-III Scales of Intelligence. VLF exposed children will be compared with those of children in control groups and their non-exposed siblings.

Results:

There were no differences in Full Scale IQ, Performance IQ and Verbal IQ between the VLF and SRIs groups (103+10vs105+12; 102+11vs102+15; 103+11vs105+12), VLF group and their siblings (105+12vs100+8; 102+15vs105+7; 105+12vs95+10), or the the SRIs group and their siblings (103+10vs104+8; 102+10vs104+8; 103+11vs106+12). Healthy controls scored significantly higher than the VLF group and the other 3 groups in Full Scale IQ, Performance IQ and Verbal IQ (P= 0.011; 0.041; and 0.028 respectively).

Conclusion:

Preliminary results show that factors such as maternal depression, genetics, and environment (not necessarily the antidepressant) are strongly associated with the child's cognitive abilities. Assessment of siblings helps to verify the impact of these factors and is possibly the strongest evidence in drug safety studies.

Support

Wyeth Pharmaceuticals

Type
Poster Session 2: Depressive Disorders
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S242
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.